Mekon expands biopsy needle lineup with semi-automatic and automatic options

Shanghai Mekon Medical Devices is promoting biopsy needle systems for tissue sampling in hospitals, diagnostic centers and OEM projects worldwide. The company says the line is built to support precise, efficient procedures as demand rises for minimally invasive diagnostics.

Why it matters: - Biopsy procedures are central to early detection of cancers, tumors and other tissue abnormalities. - Reliable tissue sampling can improve diagnostic confidence and help guide treatment planning. - Demand is rising for biopsy devices that support safer and more efficient minimally invasive procedures.

What happened: - Shanghai Mekon Medical Devices Co., Ltd. said on June 11, 2026, that it is expanding its biopsy needle offerings with semi-automatic and automatic options. - The product line is aimed at hospitals, diagnostic centers and OEM medical device brands worldwide. - Mekon said the biopsy needle solutions are designed for precise, efficient and safe tissue sampling. - The company was founded in 2009 and specializes in customized special medical needles, precision cannulas and medical consumables. - Mekon described itself as a global partner for biopsy needle systems and precision medical metal components. - More information is available in the company's announcement.

The details: - Mekon said its biopsy needle line supports soft tissue, breast, liver, lung, kidney, prostate, lymph node and bone marrow sampling. - The semi-automatic biopsy needles are built for controlled tissue collection. - The semi-automatic system allows operators to manually activate part of the biopsy mechanism. - Mekon said that design gives physicians more flexibility in sensitive or technically demanding procedures. - The semi-automatic devices use stainless steel materials and precision grinding technology. - Mekon said those features support sharp tips and smooth puncture performance. - The semi-automatic devices are designed for comfortable handling and easy operation. - The optimized needle structure is intended to help obtain intact tissue samples for pathological examination and laboratory analysis. - Mekon offers multiple gauge sizes and needle lengths for different biopsy applications and patient needs. - The automatic biopsy needles are designed for rapid tissue acquisition and procedural efficiency. - Mekon said the automatic firing mechanism helps shorten operation time and reduce patient discomfort. - The automatic systems use precision-engineered cutting cannulas to support clean tissue collection and specimen integrity. - The automatic devices are engineered for dependable activation and stable operation. - Mekon said user-friendly handling and automation can reduce physician workload during repeated procedures. - The company said safety-focused structural designs are built into the automatic biopsy line. - Automatic biopsy needles are positioned for high-volume clinical settings where efficiency and reproducibility matter.

Between the lines: - Mekon is competing on both product design and manufacturing control, not just on device format. - The company is emphasizing precision, consistency and customization because biopsy tools often need to fit specific procedures and clinical workflows. - The pitch suggests Mekon wants to serve both direct clinical users and medical brands that need private-label or OEM development.

What's next: - Mekon said it will keep investing in research, production technology and quality improvement. - The company plans to expand global partnerships. - Mekon aims to strengthen its position in biopsy needles, special medical needles and precision cannula products.